8-K current report · filed Aug 6, 2026

Compass Therapeutics, Inc. (CMPX) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1CMPX overview

Short answer

Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers quarterly and six-month financial results ended June 30, 2026.

Compass Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers quarterly and six-month financial results ended June 30, 2026
  • Exhibit 99.1 contains the detailed results and management commentary for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Tovecimig ORR reached 18.0% versus 5.3% for paclitaxel, with p-value improving to 0.0228, supporting potential BLA filing later this year
  • FDA feedback expected in Q3 2026, while full tovecimig data receive an oral ESMO presentation in October
  • CTX-8371 cohort expansions enrolling in triple-negative breast cancer, non-small cell lung cancer and Hodgkin lymphoma, with data expected in Q4
  • Cash and marketable securities $180 million at June 30, 2026, with management projecting operational funding into 2028
  • Quarterly net loss $25.2 million, R&D expenses $19.6 million and G&A expenses $7.4 million, reflecting rising clinical and pre-commercialization investment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Compass Therapeutics, Inc. 8-K filings

Get the next CMPX 8-K as it lands

Follow CMPX for push alerts, or ask the research agent what this filing means.